{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dekker EN"],"funding":["NCI NIH HHS","The Dutch Cancer Society","ZonMw"],"pagination":["znae244"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11472162"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["111(10)"],"pubmed_abstract":["<h4>Background</h4>Patients with localized (that is non-metastatic) pancreatic ductal adenocarcinoma with an inadequate response or toxicity to first-line chemotherapy may benefit from chemotherapy switch. The aim was to explore the available data on the use and effect of chemotherapy switch, as reported in the literature.<h4>Methods</h4>A systematic search was conducted in Embase, MEDLINE (Ovid), the Web of Science, Cochrane, and Google Scholar on 1 December 2023. The main outcomes were the proportion of patients who underwent chemotherapy switch and the carbohydrate antigen 19-9 response and resection, R0 resection, and ypN0 resection rates after chemotherapy switch. Data were pooled using a random-effects model.<h4>Results</h4>A total of five retrospective studies, representing 863 pati"],"journal":["The British journal of surgery"],"pubmed_title":["Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis."],"pmcid":["PMC11472162"],"funding_grant_id":["13417","P30 CA008748","10140022010009"],"pubmed_authors":["Meddouch A","Dekker EN","O'Kane GM","Wilmink JW","Qadan M","Groot Koerkamp B","O'Reilly EM","Besselink MGH","Narayan RR","Ahmami MA","de Wilde RF","Verkolf EMM","Gehrels AM","van Eijck CHJ","Homs MYV","Mostert B"],"additional_accession":[]},"is_claimable":false,"name":"Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis.","description":"<h4>Background</h4>Patients with localized (that is non-metastatic) pancreatic ductal adenocarcinoma with an inadequate response or toxicity to first-line chemotherapy may benefit from chemotherapy switch. The aim was to explore the available data on the use and effect of chemotherapy switch, as reported in the literature.<h4>Methods</h4>A systematic search was conducted in Embase, MEDLINE (Ovid), the Web of Science, Cochrane, and Google Scholar on 1 December 2023. The main outcomes were the proportion of patients who underwent chemotherapy switch and the carbohydrate antigen 19-9 response and resection, R0 resection, and ypN0 resection rates after chemotherapy switch. Data were pooled using a random-effects model.<h4>Results</h4>A total of five retrospective studies, representing 863 pati","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-07-15T17:41:19.323Z","creation":"2025-04-04T00:29:14.121Z"},"accession":"S-EPMC11472162","cross_references":{"pubmed":["39400008"],"doi":["10.1093/bjs/znae244"]}}